Enhancing Prostate Cancer Treatment: RAD51 Biomarker as a Complement to Next-Generation Sequencing
A recent study led by the Vall d’Hebron Institute of Oncology (VHIO) has revealed significant findings regarding the application of RAD51 protein testing as an adjunct to next-generation sequencing (NGS) in the treatment of metastatic prostate cancer. This …